GLP-1, or glucagon-like peptide-1, plays a crucial role in regulating our appetite and metabolism
A 2023 study in Diabetes, Obesity & Metabolism hinted that some patients can achieve significant appetite suppression and glycemic improvements even before reaching full therapeutic doses
The surging demand has made GLP-1 therapies the fastest-growing sector in diabetes/obesity pharmacotherapy
For the underlying principles, see Peptide Vial Sizes Explained
In September 2025, an investigation published by the BMJ revealed that patients were being pushed towards the black market to purchase weight-loss drugs, which it suggested may be because of poor access to drugs on the NHS and the Mounjaro price hike
39,40,446 Notably, GLP-1RAs exhibit pronounced efficacy in optimizing blood lipid profiles by effectively suppressing chylomicron secretion in the intestine, thereby mitigating the occurrence of postprandial hyperlipidemia